The development of Kcav's Mucovac is in full swing

Spray typed vaccine

It entered the second stage of the "Bio Medical Technology Support Project" and received 2 billion won in support

Omicron's defense ability and booster shot test scheduled, support is urgently needed with a new type of vaccine

A spray-type COVID-19 vaccine sprayed on the nose, not on injections, is being developed by domestic company.

 

Amid the trend of muscle injection, attention is focused on claims that mucosal immunity is more effective in defending the COVID-19 virus.

 

Kcav (CEO Song Chang-seon) announced on the 27th that Mucovac, a COVID-19 mucosal vaccine candidate that is jointly researching with Konkuk University and Bionote, has succeeded in entering the second stage of the "Bio Medical Technology Support Project" supported by Ministry of Science and ICT and National Research Foundation of Korea.

 

Accordingly, Kcav will receive 2 billion won in research funds for non-clinical trials and clinical sample production necessary for submitting the clinical trial plan (IND) of the COVID-19 mucosal vaccine Mucovac.

 

Mucovac, which is being developed by Kcav, is a candidate substance for the COVID-19 mucosal vaccine derived by combining the ECSL immune enhancer, which signed a contract with Eubiologics in March, with a new antigen developed by Bionote.

 

Mucovac confirmed that nasal administration using hACE2 TG Mice and Ferret animal Model enhances body fluidizing antibody and cellular immunity (IFN-r ELISPOT) to the COVID-19 virus.

 

In addition, as a result of conducting attack vaccination tests using Wuhan and Delta, the Mucovac vaccine group showed a 100% survival rate.

 

In particular, Kcav is planning to analyze Mucovac's ▲MoA-related analysis ▲ Evaluation of defense ability through attack inoculation after the sale of Omicron mutant and ▲ Boostershot application test (existing muscle vaccination + Mucovac inoculation).

 

Since many pathogens, including COVID-19, invade through mucous membranes, mucosal vaccines can be said to serve as the first defense mission against pathogens invading from the outside.

 

Since injection needles are not used, they can be administered safely and easily.

 

It has been argued that vaccines using nasal cavity are more effective against COVID-19 than through veins and muscles.

 

Currently, there are about 100 vaccines being developed worldwide, of which seven are vaccines using nasal cavity.

 

This is why the Korean government desperately needs support for the success of commercialization of Mucovac while global efforts are underway to overcome the COVID-19 pandemic situation.

 

An official from Kcav said, "The mucous membrane vaccine currently under development is a spray-type vaccine sprayed on the nose, not a conventional injection vaccine." He explained, "When applied with booster shots to existing vaccinations, it induces not only systemic immunity but also mucosal immunity." "We expect Mucovac to increase the ability to prevent infection through the respiratory tract of COVID-19 and respond to various mutant viruses," he said.

 

"We have already confirmed our defense against delta mutant as well as Wuhan." Kcav has already confirmed its ability to defend against the SARS-Cov-2 virus of COVID-19 mucosal vaccine candidates using ECLS immunostrengthening agents by receiving research funding from the Global Health Technology Research Fund "RIGHTFUND," co-invested by the Bill & Melinda Gates Foundation, and eight domestic life science companies in 2020.

 

Meanwhile, Kcav was established in 2014 by Professor Song Chang-sun of Veterinary Science College as the first subsidiary of Konkuk University's technology holding company.

 

It has secured a variety of vaccine pipelines for animals and humans using core platforms such as Live attenuated vaccines and Newcastle Disease vector vaccines.